Research Article

Investigation of The Effect of B-108 Contaınıng Azomethin Group On DNA Repair Gene

Volume: 44 Number: 4 December 31, 2022
Cumhuriyet Medical Journal Cover
Cumhuriyet Medical Journal
PDF Download
EN

Investigation of The Effect of B-108 Contaınıng Azomethin Group On DNA Repair Gene

Abstract

Objective: Cancer arises as a result of the failure of the mechanisms controlling normal division in a group of cells. It is known that some new synthesis compounds intended for use in cancer treatment have anti-fungal, anti-bacterial, anti-carcinogenic effects. In this study, it was aimed to apply the newly synthesized B-108 compound to the A-549 cell line and then to investigate the effect of this compound on the ERCC1 gene expression profile. Materials and Methods: Firstly, compound B-108 was synthesized in our study. Afterwards, this synthesized molecule was applied in eight different concentrations (1-100 μg/ml) in A-549 cell line and 3-(4,5-dimethylthiazol-2-yl)-2,5-yl for 24 hours, 48 hours and 72 hours. Anticancer activities were determined using diphenyltetrazolium bromide (MTT) method. Expression level of DNA repair gene (ERCC1) was determined using RT-PCR method. Results: As a result, it was determined that the molecule applied to the A-549 cell line showed the highest activity after 72 hours of incubation. It was observed that the ERCC1 gene expression of the molecule applied on lung cancer was lower than the control group. Discussion: Considering the current study results, low expression of ERCC1 shows that compound B-108 correlates with overall survival on lung cancer cells.

Keywords

References

  1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018. 68(6): p. 394-424.
  2. Kasper, D., et al., Harrison's principles of internal medicine, 19e. Vol. 1. 2015: Mcgraw-hill New York, NY, USA.
  3. Travis, W.D., E. Brambilla, and G.J.J.J.C.O. Riely, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. 2013. 31(8): p. 992-1001.
  4. Bunn, P.A., Jr., Triplet combination chemotherapy and targeted therapy regimens. Oncology (Williston Park), 2001. 15(3 Suppl 6): p. 26-32.
  5. Schabath, M.B., M.L.J.C.e. Cote, biomarkers, and prevention, Cancer progress and priorities: lung cancer. 2019. 28(10): p. 1563-1579.
  6. Scagliotti, G., et al., Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol, 2010. 28(11): p. 1835-42.
  7. Ciccia, A. and S.J. Elledge, The DNA damage response: making it safe to play with knives. Mol Cell, 2010. 40(2): p. 179-204.
  8. Rosell, R., et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. 2012. 13(3): p. 239-246.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Elif Eğilmez
0000-0003-1125-7939
Türkiye

Alakbar Huseynzada
0000-0002-6342-4260
Azerbaijan

Ulviyya Hasanova
0000-0003-1502-4227
Azerbaijan

Publication Date

December 31, 2022

Submission Date

November 11, 2022

Acceptance Date

December 19, 2022

Published in Issue

Year 1970 Volume: 44 Number: 4

DOI

https://doi.org/10.7197/cmj.1189765

IZ

https://izlik.org/JA89HL89EA

Cite

RIS / Bibtex
AMA
1.Eğilmez E, Zontul C, Huseynzada A, et al. Investigation of The Effect of B-108 Contaınıng Azomethin Group On DNA Repair Gene. CMJ. 2022;44(4):338-342. doi:10.7197/cmj.1189765